Cogent Change Receivables from 2010 to 2025
| COGT Stock | USD 8.03 0.15 1.83% |
Change Receivables | First Reported 2010-12-31 | Previous Quarter 1.8 M | Current Value 1.6 M | Quarterly Volatility 108.8 K |
Check Cogent Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cogent Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 4.8 M or Selling General Administrative of 41.5 M, as well as many indicators such as Price To Sales Ratio of 35.83, Dividend Yield of 0.0 or PTB Ratio of 3.6. Cogent financial statements analysis is a perfect complement when working with Cogent Biosciences Valuation or Volatility modules.
Cogent | Change Receivables |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.